Subsense, an AI-native neurotechnology company developing non-surgical, nanoparticle-based brain-computer interfaces (BCIs), today announced that John P. Donoghue, PhD, has joined as a scientific advisor. Through his pioneering work on BrainGate, Donoghue helped show that people with paralysis could use neural signals to control computers and robotic devices, changing the course of BCI research.

A founding figure in the field, Donoghue has spent decades advancing the science behind neural interfaces and bringing it closer to people who could benefit. His work was recognized earlier this year with the Queen Elizabeth Prize for Engineering. His decision to advise Subsense brings that experience to the company’s exploration of a BCI designed to work without surgically implanted electrodes.

“We think of John as a godfather of BCI because he helped show the world what a direct connection between the brain and technology could make possible,” said Tetiana Aleksandrova, co-founder and CEO of Subsense. “We’re honored that he has chosen to share his experience with our team. We value both his perspective on what this technology could mean for people and the rigor he brings to the questions we still need to answer.”

As a scientific advisor, Donoghue’s guidance will focus on demonstrating that nanoparticles can be localized to a target brain structure and activated to produce spatially specific stimulation, then evaluating whether that stimulation has the intended biological effect. He will also advise on the evidence needed to translate preclinical findings toward human use.

“I always divide things into the technological and the biological,” said Donoghue. “Mice can be a reasonable model to show that you could localize the particles, you can focus the stimulation and get spatially specific activation of the particles in the target structure that you’re aiming at. If you can do that, that’s pretty convincing. The biological part is then to demonstrate that this targeted stimulation can improve Parkinson’s-related symptoms in a mouse model of the disease.”

Subsense is developing two nanoparticle-based technologies in parallel. Its stimulation work is aimed initially at Parkinson’s disease and uses magnetoelectric nanoparticles designed to respond to an externally applied magnetic field. Donoghue has encouraged a stepwise research approach that establishes controlled stimulation in intact animals before evaluating effects in disease models. Separately, the company’s neural sensing work is aimed initially at communication for people with ALS who lose the ability to speak. The company’s longer-term goal is to bring sensing and stimulation together in one platform. Both technologies remain preclinical.

Beyond the immediate research questions, Donoghue pointed to the potential value of combining recording and precisely targeted stimulation for people with disabilities. “When I heard the original story, I thought this is very intriguing,” Donoghue said. “Now we want to go to something that’s much smaller and better. That’s why the vision is really important. If it works, it would be wonderful for people who have disabilities—people who are paralyzed and moving again. In the ideal, if you could get really focal stimulation, we could really reconstruct all kinds of things with stimulation and recording.”

Additional information about Subsense’s platform can be found at subsense-bci.com.

About John Donoghue, PhD

Donoghue is professor emeritus of neuroscience and engineering at Brown University and a founding member of the BrainGate research consortium. He previously served as the inaugural director of the Wyss Center for Bio- and Neuroengineering in Geneva. In 2026, he was named a recipient of the Queen Elizabeth Prize for Engineering for contributions to modern neural interfaces.

About Subsense

Subsense is an AI-native neurotechnology company developing nanoparticle-based BCIs designed to access neural activity without permanently implanted electrodes. Its nanoBCI platform combines engineered nanoparticles, external hardware, physics-based navigation modeling and AI, with separate programs under development for neural stimulation and neural reading. Subsense is currently in the preclinical stage, with its initial medical work focused on applications in Parkinson’s disease and ALS.

Media gallery

About The Author
Business Wire